NEW BRUNSWICK (dpa-AFX) - Thursday, Johnson & Johnson (JNJ) announced its
agreement to acquire Proteologix, Inc., a biotechnology company specializing in
bispecific antibodies for immune-mediated diseases.

The deal involves an $850 million cash payment, with the potential for an
additional milestone payment.

The acquisition will grant J&J access to Proteologix's bispecific antibody
programs, including PX128 targeting IL-13 and TSLP, set to enter phase 1
development for moderate to severe atopic dermatitis and asthma, as well as
PX130, a biospecific antibody targeting IL-13 and IL-22, currently in
preclinical development for moderate to severe atopic dermatitis.

The transaction is expected to be finalized in mid-year 2024.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX